Article list

#UMED-TECH-003 SUMMARY The subject of the invention is a pharmaceutical composition in the form of an oleogel containing a drug from the group of glucocorticosteroids and its use in the treatment of non-infected inflammatory conditions of the skin, also of allergic origin, dental and gynecological diseases responding to treatment with corticosteroids. BACKGROUND Known in the…

#UMED-TECH-001 SUMMARY The subject matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children. BACKGROUND Current clinical observations indicate that haemangiomas occur in about 10% of infants. They have a pronounced clinical course that can…

#CEITEC MU-004 SUMMARY RNAutriX begin with screening services, generating a proprietary dataset of RNA–small molecule interactions. Develops tools for drug design, scaffold generation, and off-target prediction. In the long term, RNAutrix will develop its own RNA-targeted therapeutics and custom HTS instrumentation, contributing unique RNA–ligand insights to accelerate the future of RNA-targeted drug discovery and development….

#CEITEC MU-002 SUMMARY A method for designing unique peptides that can selectively target and Disrupt cellular membranes of pathogens without damaging human cells. BACKGROUND Increasing incidence of antibiotic resistance in bacteria, along with a steady decline in the Discovery of new antibiotics, presents a global health challenge. There is a need for the discovery of…

#CEITEC MU-001 SUMMARY The researchers from Masaryk University developed a DNA-aptamer-based inhibitor that, in contrast to FGFR TKIs, inhibits FGFR1 but not the other existing FGFR variants (FGFR2, FGFR3, and FGFR4). In contrast to the current generation of TKIs, which targets the intracellular (kinase) domain of FGFR, the aptamer targets its extracellular domain; it significantly…